c-Ablチロシンキナーゼの自己抑制のための構造的基礎
Bhushan Nagar1, Oliver Hantschel, Matthew A Young
1Howard Hughes Medical Institute and Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA.
Cell
|March 26, 2003
まとめ
慢性骨髄性白血病 (CML) は,c-Ablの規制緩和を含む. c-Abl 1bのミリスチル化は,Srcキナーゼに似た自己抑制を誘導し,Gleevecを説明する.
科学分野:
- バイオケミストリー バイオケミストリー
- 分子生物学は分子生物学である.
- 腫瘍学 腫瘍学
背景:
- c-Ablの緩和は,慢性骨髄性白血病 (CML) に関わっている.
- c-Ablの自己抑制メカニズムは,Srcキナーゼで発見された特定のフォスフォチロジン残留物が欠如しているため,不明のままです.
- c-Ablの調節を理解することは,CMLの治療戦略にとって極めて重要です.
研究 の 目的:
- c-Abl.の自己抑制メカニズムを解明する.
- c-Abl調節の構造的基礎と,イマチニブに対するその異なる反応を調査する.
- c-Ablとc-Srcキナーゼの異なる行動に関する洞察を提供するため.
主な方法:
- c-Abl.の結晶構造の分析
- c-AblコンフォーメーションにおけるN末端ミリスチル化の役割に関する調査.
- Srcキナーゼによる比較構造分析.
主要な成果:
- c-Abl 1bのN端ミリスチル改変はキナーゼ領域に結合し,構成変化を引き起こす.
- これらの変化は,SH2とSH3ドメインのドッキングを容易にし,自己抑制状態を形成します.
- c-Ablの自己抑制構造は,非活性Srcキナーゼと類似性を共有していますが,重要な違いがあります.
結論:
- ミリスチル化がc-Ablの自己抑制に欠かせない.
- 構造的な違いは,イマチニブ (Gleevec) が Abl を抑制するが,Src を抑制しない理由を説明する.
- これは,標的型CML治療のための分子基盤を提供します.
関連する概念動画
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:19Allosteric Proteins-ATCase
Binding sites linkages can regulate a protein's function. For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis pathway,...
00:50Anaphase Promoting Complex
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
01:31The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
01:22Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...